Dr. Carbone on Pivotal Immunotherapy Studies in Lung Cancer
David Carbone, MD, PhD, director, James Thoracic Center, Ohio State University Comprehensive Cancer Center, discusses two abstracts on immunotherapy that were presented by colleagues at the 2019 World Conference on Lung Cancer in Barcelona, Spain.
David Carbone, MD, PhD, director, James Thoracic Center, Ohio State University Comprehensive Cancer Center, discusses two abstracts on immunotherapy that were presented by colleagues at the 2019 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
As a co-author on these abstracts, Carbone shared insight on the neoadjuvant study of atezolizumab (Tecentriq) before surgical resection in patients with lung cancer. The findings so far show correlation between immune biomarkers and progressive disease or patient response.
Another study presented at WCLC is a retrospective analysis of immunotherapy utilization in small cell lung cancer (SCLC). Carbone states that this study could also show an increase in the use of immunotherapy in SCLC.
